Fertility-sparing treatment in endometrial carcinoma

ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma

 A diagnosis of endometrial carcinoma in premenopausal women represents a challenge for clinicians. The standard surgical treatment for endometrial carcinoma consists of total hysterectomy with bilateral salpingo-oophorectomy, which effectively increases the chances of surviving the disease, however, devastatingly denies the woman the chance to carry a pregnancy. Fertility-sparing treatment can be a temporary option for these patients.

ESHRE, together with the European Society of Gynaecological Oncology (ESGO) and the European Society for Gynaecological Endoscopy (ESGE) have developed clinically relevant and evidence-based guidelines, focusing on key aspects of fertility-sparing treatment in order to improve the quality of care for women with endometrial carcinoma.

The multidisciplinary international group consisted of experts practising clinicians, researchers in the fields of gynaecological oncology, human reproduction, endoscopy and histopathology. The development group was chaired by Prof. Alexandros Rodolakis (ESGO, Greece), Dr. Kirsten Louise Tryde Macklon (ESHRE, Denmark) and Prof. Giovanni Scambia (ESGE, Italy).

The recommendations cover patients selection, tumour clinicopathological characteristics, treatment, and special issues.

The guideline is simultaneously published in the International Journal of Gynecological Cancer and Facts, Views and Vision in ObGyn.